The company has secured 506 marketing approvals for its oncology products across 76 countries.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Marks the World Head & Neck Cancer Day at the OCTF Conference
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
CARA is a data and content management platform that helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
AIIMS established in Bilaspur, Nagpur, Rae Bareli and Gorakhpur
Subscribe To Our Newsletter & Stay Updated
